Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1 /nuclear factor-kappa B axis

International Journal of Medical Sciences

Volumn 10, Issue 7, 2013, Pages 812-824

  Yang, Dongfang ^a   Yuan, Jia ^a   Liu, Gan ^a,b   Ling, Zhiyu ^a   Zeng, Haiyan ^c   Chen, Yunqing ^a   Zhang, Yue ^a   She, Qiang ^a   Zhou, Xue ^d  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b Department of Cardiology   (China)

^c SICHUAN UNIVERSITY   (China)

^d CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrosis; Irbesartan; Nuclear factor kappa B (NF B); Platelet derived growth factor (PDGF); Rac1; Simvastatin

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; COLLAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN TYPE III ALPHA 1; RAC1 PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; FEMALE; FIBROSIS; HEART ATRIUM FIBRILLATION; HEART ATRIUM FIBROSIS; HEART LEFT ATRIUM; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE;

ATRIAL FIBROSIS; IRBESARTAN; NUCLEAR FACTOR-KAPPA B (NF-ΚB); PLATELET-DERIVED GROWTH FACTOR (PDGF); RAC1; SIMVASTATIN.;

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BASE SEQUENCE; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART ATRIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NF-KAPPA B; PLATELET-DERIVED GROWTH FACTOR; RAC1 GTP-BINDING PROTEIN; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84877261482     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5931     Document Type: Article

References (27)

1. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802-809.
2. Corradi D, Callegari S, Maestri R, Benussi S, Alfieri O. Structural remodeling in atrial fibrilation. Nat Clin Pract Cardiovasc Med. 2008;5:782-796.
3. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodelin during atrial fibrillation. Cardiovasc Res. 2002;54:230-246.
4. Nattel S, Burstein B, Dobrev D. Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications. Circ Arrhythm Electrophysiol. 2008;1:62-73.
5. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
6. Verheule S, Sato T, Everett TIV, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by over-expression of TGF-beta1. Circ Res. 2004;94:1458-1465.
7. Burstein B, Libby E, Calderone A, Nattel S. Differential Behaviors of Atrial Versus Ventricular Fibroblasts: A Potential Rolefor Platelet-Derived Growth Factor in Atrial-Ventricular Remodeling Differences. Circulation. 2008;117:1630-41.
8. Sulciner, DJ, Irani K, Yu ZX, Ferrans VJ, Goldschmidt-Clermont P, and Finkel T. Rac1 regulates a cytokine-stimulated redox-dependent pathway necessary for NF-kappaB activation. Mol Cell Biol. 1996;16:7115-7121.
9. Adam O, Frost G, Custodis F, et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol. 2007;50:359-367.
10. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2004;93:780-782.
11. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92:1379-1383.
12. Gao G, Dudley SC Jr. Redox regulation, NF-kappa B, and atrial fibrillation. Antioxid Redox Signal. 2009;11:2265-77.
13. Chien-hui Liao, Hiroshi Akazawa, Masaji Tamagawa, Kaoru Ito. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2010;120:242-253.
14. Tsai CT, Lai LP, Kuo KT, et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation. 2008;117:344-55.
15. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512-518.
16. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119:2146-2152.
17. Yin YH, Dalal D, Liu ZC, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006;27:1841-1846.
18. Qu YC, Du YM, Wu SL, et al. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J. 2009;23:1-6.
19. Adam O, Lavall D, Theobald K, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol. 2010;55:469-80.
20. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106: 331-336.
21. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur Heart J. 2003;24:2090-2098.
22. Simm A, Diez C. Density dependent expression of PDGF-A modulates the angiotensin II dependent proliferation of rat cardiac fibroblasts. Basic Res Cardiol.1999;94:464-471.
23. Yoshiharu Higuchi, Kinya Otsu, Kazuhiko Nishida et al. The Small GTP-binding Protein Rac1 Induces Cardiac Myocyte Hypertrophy through the Activation of Apoptosis Signal-regulating Kinase 1 and Nuclear Factor-B. J Boil Chem. 2003;23:20770-20777.
24. Nadruz Jr W, Lagosta VJ, Moreno Jr H, Coelho OR, Franchini KG. Simvastatin prevents load-induced protein tyrosine nitration in overloaded hearts. Hypertension.2004;43:1060-6.
25. Yagi S, Akaike M, Aihara K et al. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension. 2010;55:918-23.
26. Tan AY, Zimetbaum P. Atrial fibrillation and atrial fibrosis. J Cardiovasc Pharmacol.2011;57:625-9.
27. Shiroshita-Takeshita A, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovas Res. 2007;74:75-84.